Diagnosis and Management of Progressive Supranuclear Palsy

ABSTRACT

Because of the relevance of an early and accurate diagnosis for prognosis, management, and participation of patients in research, the classical clinical features-features that should raise suspicion of progressive supranuclear palsy (PSP) and those that should make the diagnosis of PSP unlikely-are discussed in this article. The accuracy of currently used clinical diagnostic criteria and the role of laboratory investigations in the diagnosis of PSP are reviewed. New terminology for the clinical diagnostic criteria for PSP is proposed. The main neuropathologic and neurochemical features supporting current main symptomatic and hypothesized experimental biologic therapies are suggested.

KEYWORD

Progressive supranuclear palsy - diagnosis - treatment - atypical Parkinsonian disorders

REFERENCES

• 1 Steele J C, Richardson J C, Olszewski J. Progressive supranuclear palsy.  Arch Neurol . 1964;  10 333-359
• 2 Steele J. Introduction. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 3-14
• 3 Litvan I, Agid Y, Jankovic J. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).  Neurology . 1996;  46 922-930
• 4 Golbe L I, Davis P H, Schoenberg B S, Duvoisin R C. Prevalence and natural history of progressive supranuclear palsy.  Neurology . 1988;  38 1031-1034
• 5 Bower J H, Maraganore D M, McDonnell S K, Rocca W A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmstead County, Minnesota, 1976 to 1990.  Neurology . 1997;  49 1284-1288
• 6 Schrag A, Ben-Shlomo Y, Quinn N P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.  Lancet . 1999;  354 1771-1775
• 7 Litvan I, Mangone C A, McKee A. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.  J Neurol Neurosurg Psychiatry . 1996;  60 615-620
• 8 Colosimo C, Albanese A, Hughes A J, de Bruin M V, Lees A J. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.  Arch Neurol . 1995;  52 294-298
• 9 Collins S J, Ahlskog J E, Parisi J E, Maraganore D M. Progressive supranuclear palsy: neuropathologically based diagnostic criteria.  J Neurol Neurosurg Psychiatry . 1995;  58 167-173
• 10 Litvan I, Grimes D A, Lang A E. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. In: Litvan I, Goetz CK, Lang AE, eds. Advances in Neurology Philadelphia: Lippincott Williams & Wilkins; 2000: 183-196
• 11 Nuwer M. Progressive supranuclear palsy despite normal eye movements.  Arch Neurol . 1981;  38 784
• 12 Dubas F, Gray F, Escourolle R. Maladie de Steele-Richardson-Olszewski sans ophtalmoplégie.  Rev Neurol . 1983;  139 407-416
• 13 Matsuo H, Takashima H, Kishikawa M. Pure akinesia: an atypical manifestation of progressive supranuclear palsy.  J Neurol Neurosurg Psychiatry . 1991;  54 397-400
• 14 Riley D E, Fogt N, Leigh R J. The syndrome of ``pure akinesia'' and its relationship to progressive supranuclear palsy.  Neurology . 1994;  44 1025-1029
• 15 Leiguarda R C, Pramstaller P P, Merello M. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism.  Brain . 1997;  120 75-90
• 16 Bergeron C, Pollanen M S, Weyer L, Lang A E. Cortical degeneration in progressive supranuclear palsy: a comparison with cortical-basal ganglionic degeneration.  J Neuropathol Exp Neurol . 1997;  56 726-734
• 17 Litvan I, Agid Y, Calne D. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Report of the NINDS-SPSP International Workshop.  Neurology . 1996;  47 1-9
• 18 Lopez O L, Litvan I, Catt K E. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.  Neurology . 1999;  53 1292-1299
• 19 Hauw J J, Daniel S E, Dickson D. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).  Neurology . 1994;  44 2015-2019
• 20 Litvan I, Hauw J J, Bartko J J. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.  J Neuropathol Exp Neurol . 1996;  55 97-105
• 21 Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively ``exon 10'' isoforms.  J Neurochem . 1999;  72 1243-1249
• 22 Spillantini M G, Crowther R A, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies.  Proc Natl Acad Sci U S A . 1998;  95 7737-7741
• 23 Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.  Philos Trans R Soc Lond B Biol Sci . 1999;  354 1101-1118
• 24 Vidailhet M, Rivaud S, Gouider-Khouja N. Eye movements in parkinsonian syndromes.  Ann Neurol . 1994;  35 420-426
• 25 Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy: a comparison with Parkinson's disease.  Arch Neurol . 1988;  45 1194-1199
• 26 Pierrot-Deseilligny C, Turell E, Penet C. Increased wave P 300 latency in progressive supranuclear palsy.  J Neurol Neurosurg Psychiatry . 1989;  52 656-658
• 27 Johnson R J, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition.  Neurology . 1991;  41 1257-1262
• 28 Johnson R J. Event-related brain potentials. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 122-154
• 29 Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders.  J Neural Transm Suppl . 1994;  42 93-110
• 30 Schrag A, Good C D, Miszkiel K. Differentiation of atypical parkinsonian syndromes with routine MRI.  Neurology . 2000;  54 697-702
• 31 Tedeschi G, Litvan I, Bonavita S. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.  Brain . 1997;  120 1541-1552
• 32 D'Antona R, Baron J C, Samson Y. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.  Brain . 1985;  108 785-799
• 33 Foster N L, Gilman S, Berent S. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography.  Ann Neurol . 1988;  24 399-406
• 34 Blin J, Baron J C, Dubois B. Positron emission tomography study in progressive supranuclear palsy: brain hypometabolic pattern and clinicometabolic correlations.  Arch Neurol . 1990;  47 747-752
• 35 Verny M, Duyckaerts C, Agid Y, Hauw J J. The significance of cortical pathology in progressive supranuclear palsy: clinicopathological data in 10 cases.  Brain . 1996;  119 1123-1136
• 36 De Volder G A, Francard J, Laterre C. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration.  Ann Neurol . 1989;  26 239-247
• 37 Baron J C, Maziere B, Loc'h C. Loss of striatal [⁷⁶Br] bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy.  J Cereb Blood Flow Metab . 1986;  6 131-136
• 38 Leenders K L, Frackowiak R S, Lees A J. Steele-Richardson-Olszewski syndrome: brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.  Brain . 1988;  111 615-630
• 39 Brooks D J, Ibanez V, Sawle G V. Differing patterns of striatal ¹⁸F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.  Ann Neurol . 1990;  28 547-555
• 40 Brooks D J. PET studies in progressive supranuclear palsy.  J Neural Transm Suppl . 1994;  42 119-134
• 41 Agid Y, Javoy-Agid F, Ruberg M. Progressive supranuclear palsy: anatomoclinical and biochemical considerations.  Adv Neurol . 1987;  45 191-206
• 42 Litvan I. Progressive supranuclear palsy revisited.  Acta Neurol Scand . 1998;  98 73-84
• 43 Kompoliti K, Goetz C G, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy.  Arch Neurol . 1998;  55 1099-1102
• 44 Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.  Neurology . 1983;  33 505-507
• 45 Weiner W J, Minagar A, Shulman L M. Pramipexole in progressive supranuclear palsy.  Neurology . 1999;  52 873-874
• 46 Litvan I, Chase T N. Traditional and experimental therapeutic approaches. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 254-269
• 47 Litvan I. Cholinergic approaches to the treatment of progressive supranuclear palsy.  J Neural Transm Suppl . 1994;  42 275-281
• 48 Litvan I, Blesa R, Clark K. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.  Ann Neurol . 1994;  36 55-61
• 49 Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy.  Neurology . 1991;  41 986-991
• 50 Conrad C, Andreadis A, Trojanowski J Q. Genetic evidence for the involvement of tau in progressive supranuclear palsy.  Ann Neurol . 1997;  41 277-281
• 51 Baker M, Litvan I, Houlden H. Association of an extended haplotype in the tau gene with progressive supranuclear palsy.  Hum Mol Genet . 1999;  8 711-715
• 52 Hutton M, Lendon C L, Rizzu P. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17.  Nature . 1998;  393 702-705
• 53 Odetti P, Garibaldi S, Norese R. Lipoperoxidation is selectively involved in progressive supranuclear palsy.  J Exp Neurol Neuropathol . 2000;  59 393-397
• 54 Albers D S, Augood S J, Park L C. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment.  J Neurochem . 2000;  74 878-881
• 55 Swerdlow R H, Golbe L I, Parks J K. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.  J Neurochem . 2000;  75 1681-1684
• 56 Albers D S, Augood S J, Martin D M. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.  J Neurochem . 1999;  73 881-884
• 57 Loeffler D A, LeWitt P A, Juneau P L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.  Brain Res . 1996;  738 265-274
• 58 Sian J, Dexter D T, Lees A J. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.  Ann Neurol . 1994;  36 348-355
• 59 Smith M A, Kutty R K, Richey P L. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.  Am J Pathol . 1994;  145 42-47
• 60 Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.  Pathol Biol (Paris) . 1996;  44 57-64
• 61 Kordower J H, Palfi S, Chen E Y. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.  Ann Neurol . 1999;  46 419-424
• 62 Lieberman D M, Laske D W, Morrison P, Bankiewicz K S, Oldfield E H. Convection-enhanced distribution of large molecules in gray matter during interstitial infusion.  J Neurosurg . 1995;  82 1021-1029
• 63 Litvan I, Dickson D W, Buttner-Ennever J A, participants in the First International Brainstorming Conference on PSP. Research goals in progressive supranuclear palsy.  Mov Disord . 2000;  15 446-458